Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Joe Bolen"'
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, severalgroups are pursuing the development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01d07dcfcf19a153c02b55def60b337b
https://doi.org/10.1158/0008-5472.c.6500702
https://doi.org/10.1158/0008-5472.c.6500702
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
Supplementary Data, Figure Legends 1-3 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::047537a2a69c0cda17d48c1520f0a30d
https://doi.org/10.1158/0008-5472.22383908
https://doi.org/10.1158/0008-5472.22383908
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
Supplementary Figure 3 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::167a752aed7cf54345175b4a7222531b
https://doi.org/10.1158/0008-5472.22383899.v1
https://doi.org/10.1158/0008-5472.22383899.v1
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
Supplementary Figure 1 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b97042635affb441b3a3b3d21b28b2
https://doi.org/10.1158/0008-5472.22383905.v1
https://doi.org/10.1158/0008-5472.22383905.v1
Autor:
Joe Bolen, Mark Rolfe, Mark Manfredi, Li Yu, Paul Fleming, Larry Dick, Christopher Tsu, Khristofer Garcia, Jonathan Blank, Jane Liu, Frank Bruzzese, Paul Hales, Yu Yang, Jie Yu, Allison Berger, Michael Fitzgerald, Bret Bannerman, Yueying Cao, Edmund C. Lee, Erik Kupperman
Supplementary Figure 2 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15517bdacedd9fc09e61f244c92924e5
https://doi.org/10.1158/0008-5472.22383902.v1
https://doi.org/10.1158/0008-5472.22383902.v1
Autor:
Bret Bannerman, Larry Dick, Mark Rolfe, Li Yu, Paul Hales, Jie Yu, Frank J. Bruzzese, Mark Manfredi, Edmund Lee, Michael Fitzgerald, Yueying Cao, Khristofer Garcia, Jane Liu, Joe Bolen, Erik Kupperman, Jonathan L. Blank, Paul E. Fleming, Yu Yang, Christopher Tsu, Allison Berger
Publikováno v:
Cancer Research. 70:1970-1980
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, severalgroups are pursuing the development
Autor:
Andy Dorner, Santhosh Palani, John Donovan, Joe Bolen, Doanh Mai, John Bradley, Keisuke Kuida, Carl Boand, Jean Courtemanche, Wen Chyi Shyu, Doug Bowman, Jeffrey Ecsedy, Arijit Chakravarty, Derek Blair, Jerome T. Mettetal
Publikováno v:
Cancer Research. 73:5229-5229
Emerging clinical evidence suggests that tumor response to treatment occurs along stochastic, evolutionary trajectories, with the amplification of pre-existing clones of resistant cells being shown to be responsible for treatment failure in a number
Publikováno v:
Cancer Research. 71:LB-371
Protein SUMOylation is a conserved ubiquitin-like protein posttranslational modification pathway catalyzed by the SUMO enzymatic cascade. Previous studies have indicated SUMO pathway genes are highly expressed in cancer and are required for developme